AdBio is a venture capital firm that specializes in early-stage investments in promising life sciences startups across Europe, with a particular focus on therapeutics-oriented projects. Their strategy involves combining seed investments with robust entrepreneurial support to transform academic research into viable ventures and accelerate company growth.
75% of their portfolio is in Biotech & Life Sciences. Deal activity increased 100% year-over-year (2 deals in the last 12 months). Their most common stage is series-a (50% of deals). Average disclosed round size is $66.4M (across 4 rounds with reported amounts).
Portfolio
4
Fund Size
$185.2M
Top Stage
Series A
Last 12 Mo
2
Portfolio Breakdown
Stage Distribution
Investment Activity
DealsAvg Round Size
Portfolio
4 investments
| Company | Round | Amount | Date |
|---|---|---|---|
 Tenpoint Therapeutics | Series B | $85M | Jan 2026 |
 ARTHEx Biotech S.L. | Series B | $87M | Sep 2025 |
| AAugustine Therapeutics | Series A | $77.7M | Mar 2025 |
| TTridek-One | Series A | $16M | Sep 2022 |
Top Co-Investors
Bpifrance2 shared
Novo Holdings1 shared
Jeito Capital1 shared
Asabys1 shared
Eli Lilly and Company1 shared
PMV1 shared
Hillhouse Capital1 shared
British Business Bank1 shared
EQT Life Sciences1 shared
Sofinnova Partners1 shared
F-Prime Capital1 shared
Eight Roads Ventures1 shared
Qiming Venture Partners USA1 shared
Columbus Venture Partners1 shared
Hadean Ventures1 shared
Pureos Bioventures1 shared
Bioqube Ventures1 shared
Last updated: 7 April 2026